Skip to content

Stress Reduction Program in Patients With Malignant Brain Tumors and Their Family Caregivers

Evaluation of a Stress Reduction Program in Patients With Malignant Brain Tumors and Their Family Caregivers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00376818
Enrollment
4
Registered
2006-09-15
Start date
2006-06-30
Completion date
2008-04-30
Last updated
2012-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain and Central Nervous System Tumors, Psychosocial Effects of Cancer and Its Treatment

Keywords

psychosocial effects of cancer and its treatment, adult anaplastic astrocytoma, adult anaplastic ependymoma, adult anaplastic oligodendroglioma, adult giant cell glioblastoma, adult gliosarcoma, adult medulloblastoma, adult anaplastic meningioma, adult papillary meningioma, adult mixed glioma, recurrent adult brain tumor, adult glioblastoma, adult grade III meningioma

Brief summary

RATIONALE: Yoga, meditation, and breathing exercises may help lower stress and improve quality of life in patients with malignant brain tumors and their family caregivers. PURPOSE: This clinical trial is studying how well a stress reduction program works to improve the quality of life of patients with malignant brain tumors and their family caregivers.

Detailed description

OBJECTIVES: Primary * Determine whether regular practice of a stress reduction program for 8 weeks improves the quality of life of patients with malignant brain tumors. Secondary * Determine whether regular practice of a stress reduction routine decreases perception of stress and anxiety and stress- and inflammation-related hormones in both patients with malignant brain tumors and their primary family caregivers. OUTLINE: This is a pilot study. Patients and caregivers receive a 90-minute stress-reduction session once a week for 8 weeks. Each session comprises an educational session on stress reduction and yoga therapy comprising specific yoga postures, breathing exercises, and relaxation and meditation. Quality of life, stress, anxiety, and levels of stress-related hormones (cortisol, dehydroepiandrosterone sulfate \[DHEAS\], and melatonin) are assessed at baseline and at week 8. After completion of study treatment, patients and caregivers are followed at 6 and 12 months. PROJECTED ACCRUAL: A total of 14 caregiver/patient pairs will be accrued for this study.

Interventions

BEHAVIORALexercise intervention

All participants will convene once per week for 8 weeks for a 90-minute session that will be based on yoga principles for a stress reduction.

OTHEReducational intervention

A 15-minute educational session on a particular topic (mind-body connection; fight or flight response; relaxation response; the science and philosophy of yoga; the science of meditation; sleeping well; mindfulness; the healer within - how to harness your innate healing potential).

OTHERphysiologic testing

Both patients and family caregivers will complete Perceived Stress Scale (PSS) and Beck Anxiety Inventory (BAI) questionnaires.

OTHERmanagement of therapy complications

Brain Cancer module-20 questionnaire to assesses problems specific to brain tumor.

Meditation practice in this study will consist of 15 minutes of body scan to completely relax the body from head to toe and will be followed by 15 minute silence during which the study participants will maintain awareness of their breath, bodily sensations and thoughts as they spontaneously arise. The remainder of the class will be devoted to a group discussion of personal reflections and challenges.

PROCEDUREMeasurement of stress-related hormones

Measurements of stress-related hormones: Stress hormones cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin will be measured in saliva because their levels in saliva accurately reflect blood levels (Carlson et al, 2004). The non-invasive saliva collection method by cotton swabs (Salivette® by Sardstedt Inc.) will be used in this study.

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Case Comprehensive Cancer Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed malignant brain tumor of 1 of the following subtypes: * Anaplastic astrocytoma * Glioblastoma multiforme * Astrocytoma WHO grade IV * Malignant meningioma * Anaplastic oligodendroglioma * Anaplastic oligoastrocytoma * Gliosarcoma * Anaplastic ependymoma * Medulloblastoma * Caregivers must meet the following criteria: * Primary family caregiver * Age 18 and over PATIENT CHARACTERISTICS: * Karnofsky performance status 70-100%\* * Absolute neutrophil count ≥ 1,500/mm³\* * Platelet count ≥ 100,000/mm³\* * Bilirubin ≤ 2 times normal\* * Alkaline phosphatase ≤ 2 times normal\* * SGOT ≤ 3 times normal\* * BUN or creatinine ≤ 1.5 times normal\* * No other prior (within the past 3 years) or concurrent malignancies except for surgically cured carcinoma in situ of the cervix or nonmelanoma skin cancer\* * Not pregnant\*\* * Negative pregnancy test\*\* * Fertile patients must use effective contraception\*\* * No active infection\*\* * No medical condition that would interfere with the practice of yoga and meditation\*\* NOTE: \*Patient NOTE: \*\*Patient and caregiver PRIOR CONCURRENT THERAPY: * No other prior or concurrent stress reduction techniques using yoga or meditation\* * Concurrent standard or investigational chemotherapy, hormonal therapy, immunotherapy, biologic agents, or other complementary and alternative therapies as the primary or adjuvant treatment allowed (patient) * No concurrent glucocorticoids (caregiver) * Concurrent dexamethasone allowed provided the daily dose is \< 2 mg/day (patient) * No concurrent dehydroepiandrosterone sulfate (DHEAS) and/or melatonin supplements\* NOTE: \*Patient and caregiver

Design outcomes

Primary

MeasureTime frame
Quality of life as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Items (EORTC QLQ-C30) and Brain Cancer Module-2012 months

Secondary

MeasureTime frame
Decrease in stress- and inflammation-related hormones in patients and their primary family caregivers as measured by saliva samples12 months
Decrease in perception of stress and anxiety in patients and their primary family caregivers as measured by the Perceived Stress Scale and Beck Anxiety Inventory questionnaires12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026